Bioactive compounds present in drugs marketed for the control of diabetes, such as sitagliptin and alogliptin, act by inhibiting the enzyme DPP-IV or mimicking incretins, which are hormones responsible for stimulating insulin secretion by pancreatic β cells in the presence of glucose. The gene discussed is INS; the disease is diabetes mellitus.